Fig. 5From: Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsUpstream regulator analysis using Ingenuity pathway software in MOLM-13 cells exposed to idasanutlin (100 nM) for 6Â h predicted a TP53 pathway activation and b CCND1 pathway inhibition. Bcl-2 inhibition by venetoclax did not result in changes of gene transcriptionBack to article page